A well‐tolerated 5‐FU‐based treatment subsequent to severe capecitabine‐induced toxicity in a DPD‐deficient patient
Open Access
- 3 April 2008
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 65 (6) , 966-970
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapyBritish Journal of Clinical Pharmacology, 2007
- Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulationPharmacogenetics and Genomics, 2007
- 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiencyCancer Letters, 2007
- Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicityBritish Journal of Clinical Pharmacology, 2007
- Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceMolecular Cancer Therapeutics, 2006
- Pharmacogenetics of Capecitabine in Advanced Breast Cancer PatientsClinical Cancer Research, 2006
- An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practiceJournal of Chromatography B, 2005
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Association of intratumoral pharmacokinetics of fluorouracil with clinical responseThe Lancet, 1994